Forskning ved Københavns Universitet - Københavns Universitet

Forside

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
OriginalsprogEngelsk
TidsskriftLancet
Vol/bind362
Udgave nummer9391
Sider (fra-til)1184-91
Antal sider8
ISSN0140-6736
DOI
StatusUdgivet - 11 okt. 2003

ID: 34102049